Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CC 38

Next Previous
Drug Profile

CC 38

Alternative Names: CC-38

Latest Information Update: 26 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CuraCell
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colorectal cancer; Prostate cancer
  • Preclinical Solid tumours

Most Recent Events

  • 13 Nov 2025 Phase-I/II clinical trials in Colorectal cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in Germany (IV) (NCT07255664) (CTIS2025-521227-70-00)
  • 13 Nov 2025 Phase-I/II clinical trials in Prostate cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (IV) (NCT07255664) (CTIS2025-521227-70-00)
  • 02 Oct 2025 Curacell has patent pending for "Dosage regimen comprising administration of tumor infiltrating lymphocytes and a checkpoint inhibitor" in the European Union, South Korea, Australia, Japan, China, Mexico and other countries worldwide

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top